Review of 10 years of research on breast cancer patients:Focus on indoleamine 2,3-dioxygenase

Therapeutic manipulation of the immune system in cancer has been an extensive area of research in the field of oncoimmunology.Immunosuppression regulates antitumour immune responses.An immunosuppressive enzyme,indoleamine 2,3-dioxygenase(IDO)mediates tumour immune escape in various malignancies including breast cancer.IDO upregulation in breast cancer cells may lead to the recruitment of regulatory T(T-regs)cells into the tumour microenvironment,thus inhibiting local immune responses and promoting metastasis.Immunosuppression induced by myeloid derived suppressor cells activated in an IDOdependent manner may enhance the possibility of immune evasion in breast cancer.IDO overexpression has independent prognostic significance in a subtype of breast cancer of emerging interest,basal-like breast carcinoma.IDO inhibitors as adjuvant therapeutic agents may have clinical implications in breast cancer.This review proposes future prospects of IDO not only as a therapeutic target but also as a valuable prognostic marker for breast cancer.

Myricetin inhibits interferon-γ-induced programmed death ligand-1 and indoleamine 2,3-dioxygenase 1 expression in lung cancer cells

OBJECTIVE Programmed death ligand-1(PD-L1)and indoleamine 2,3-dioxygenase 1(IDO1)are immune checkpoints which can be induced by interferon-γ(IFN-γ)in the tumor microenvironment,leading to immune escape of tumors.Myricetin(MY)is a flavonoid distributed in many edible and medicinal plants.The aim of this study is to clarify the effect and the mechanism of MY on inhibiting IFN-γ-induced PD-L1 and IDO1 in lung cancer cells.METHODS Expressions of PD-L1 and major histocompatibility complex-I(MHC-I)were evaluated by flow cytometry and Western blotting,and the expression of IDO1 was measured by Western blotting.qRT-PCR was used to detect their mRNA levels.The function of T cells was evaluated using a co-culture system consist of lung cancer cells and the Jurkat-PD-1 T cell line that overexpressing PD-1.Molecular docking analysis,Western blotting and immunofluorescence were used for mechanism study.RESULTS MY potently inhibited IFN-γ-induced PD-L1 and IDO1 expression in human lung cancer cells,while didn't show obvious effect on the expression of MHC-I.In addition,MY restored the survival,proliferation,CD69 expression and interleukin-2(IL-2)secretion of Jurkat-PD-1 T cells suppressed by IFN-γ-treated lung cancer cells in the co-culture system.Mechanistically,IFN-γup-regulated PD-L1 and IDO1 at the transcriptional level through the JAK-STAT-IRF1 axis,which was targeted and inhibited by MY.CONCLUSION Our research revealed a new insight into the anti-tumor effects of MY which inhibited IFN-γ-induced PD-L1 and IDO1 expression,supporting the potential of MY in anti-tumor immunotherapy.

Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma

Tumor cells induce an immunosuppressive microen-vironment which leads towards tumor immune escape. Understanding the intricacy of immunomodulation by tumor cells is essential for immunotherapy. Indoleamine 2,3-dioxygenase(IDO) is an immunosuppressive enzyme which mediates tumor immune escape in various cancers including hepatocellular carcinoma(HCC). IDO up-regulation in HCC may lead to recruitment of regulatory T-cells into tumor microenvironment and therefore inhibit local immune responses and promote metastasis. HCC associated fibroblasts stimulate natural killer cells dysfunction through prostaglandin E2 and subsequently IDO promotes favorable condition for tumor metastasis. IDO up-regulation induces immuno-suppression and may enhance the risk of hepatitis C virus and hepatitis B virus induced HCC. Therefore, IDO inhibitors as adjuvant therapeutic agents may have clinical implications in HCC. This review proposes future prospects of IDO not only as a therapeutic target but also as a prognostic marker for HCC.

Inhibition of allogeneic T-cell response by Kupffer cells expressing indoleamine 2,3-dioxygenase

AIM:To explore the possibility and mechanism of inhibiting allogeneic T-cell responses by Kupffer cells (KC)pretreated with interferon-γ(IFN-γ)in vitro. METHODS:The expressions of indoleamine 2,3-dioxygenase(IDO)mRNA and FasL mRNA in KC pretreated with IFN-γwere studied with real-time polymerase chain reaction(PCR).The catabolism of tryptophan by IDO from KC was analyzed by high performance liquid chromatography.Allogeneic T-cell response was used to confirm the inhibition of KC in vitro.The proliferation of lymphocytes was detected using[ 3 H]thymidine incorporation.Cell cycle and lymphocyte apoptosis were evaluated by flow cytometric assay. RESULTS:Real-time PCR revealed IDO mRNA and FasL mRNA expressions in KC pretreated with IFN-γ,and IDO catabolic effect was confirmed by a decrease in tryptophan and increase in kynurenine concentration. KC expressing IDO and FasL in BABL/c mice acquired the ability to suppress the proliferation of T-cells from C57BL/6,which could be blocked by addition of 1-methyl-tryptophan and anti-FasL antibody.KC expressing IDO could induce allogeneic T-cell apoptosisCONCLUSION:In addition to Fas/FasL pathway,IDO may be another mechanism for KC to induce immune tolerance.

Mesenchymal-epithelial Transition Factor Regulates Monocyte Function during Mycobacterial Infection via Indoleamine 2,3-dioxygenase

Objective Mycobacterium tuberculosis(Mtb),the causative agent of tuberculosis(TB),causes an estimated 1.6 million human deaths annually,but the pathogenesis of TB remains unclear.Immunity plays a critical role in the onset and outcome of TB.This study aimed to uncover the roles of innate and adaptive immunity in TB.Methods The gene expression profiles generated by RNA sequencing from human peripheral blood mononuclear cells(PBMCs)stimulated with or without Mtb strain H37Rv antigens were analyzed.A total of 973 differentially expressed mRNAs were identified.Results The differentially expressed genes were enriched in innate immunity signaling functions.The mesenchymal-epithelial transition factor(MET)gene was significantly upregulated in CD14^(+)monocytes.A MET inhibitor improved the uptake of the BCG strain by monocytes and macrophages as well as inhibited the expression of indoleamine 2,3-dioxygenase(IDO).The expression of IDO was increased in PBMCs stimulated with Mtb antigens,and the IDO inhibitor promoted the expression of CD40,CD83,and CD86.Conclusion Our results might provide clues regarding the immunomodulatory mechanisms used by Mtb to evade the host defense system.

Molecular Cloning and Characterization of Porcine Indoleamine 2,3-Dioxygenase and Its Expression in Various Tissues

In order to confirm the existence of indoleamine 2,3-dioxygenase(IDO) gene in swine,and to clone the novel gene followed by the molecule structure properties and expression pattern analysis,the porcine mRNA sequences homologous to human IDO were obtained from GenBank database by bioinformatics method.By using RT-PCR,the IDO gene was cloned from porcine endothelial cell line and the accuracy of the nucleic acid sequence was confirmed,and the expression pattern of the gene was detected.The three-dimensional structure model of porcine IDO was built referring to the tertiary structure of human IDO using biological sequence analysis software and database.The results showed that the porcine IDO was identified by sequencing.The nucleotide sequences were confirmed as a novel gene after submitted to Genbank.Porcine IDO was expressed in the lung,thymus,epididymis and anterior chamber with a basic level,however in peripheral blood mononuclear cells(PBMCs) the IDO gene was highly expressed.The three-dimensional structure model of porcine IDO was similar to that of human IDO.It was suggested that identification of the structure information of porcine IDO is essential to further investigate the immunologic function of the gene.Study of IDO on NK cells-mediated xenograft rejection will be a novel therapeutic target for the development of xenotransplantation.

Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients

BACKGROUND Forkhead box P3(FOXP3)is a specific marker for immunosuppressive regulatory T(T-reg)cells.T-regs and an immunosuppressive enzyme,indoleamine 2,3-dioxygenase(IDO),are associated with advanced disease in cancer.AIM To evaluate the co-expression of FOXP3 and IDO in triple negative breast cancer(TNBC)with respect to hormone-positive breast cancer patients from Pakistan.METHODS Immunohistochemistry was performed to analyze the expression of FOXP3,IDO,estrogen receptor,progesterone receptor,and human epidermal growth factor receptor on tissues of breast cancer patients(n=100):Hormone-positive breast cancer(n=51)and TNBC(n=49).A total of 100 patients were characterized as FOXP3 negative vs positive and further categorized based on low,medium,and high IDO expression score.Univariate and multivariate logistic regression models were used.RESULTS Out of 100 breast tumors,25%expressed FOXP3 positive T-regs.A significant coexpression of FOXP3 and IDO was observed among patients with TNBC(P=0.01)compared to those with hormone-positive breast cancer.Two variables were identified as significant independent risk factors for FOXP3 positive:IDO expression high(adjusted odds ratio(AOR)5.90;95%confidence interval(CI):1.22-28.64;P=0.03)and TNBC(AOR 2.80;95%CI:0.96-7.95;P=0.05).CONCLUSION Our data showed that FOXP3 positive cells might be associated with high expression of IDO in TNBC patients.FOXP3 and IDO co-expression may also suggest its involvement in disease,and evaluation of FOXP3 and IDO expression in TNBC patients may offer a new therapeutic option.

Relationship of Abortion and the Expression of Indoleamine 2,3- dioxygenase (IDO) in Villus and Syncytiotrophoblasts

Objective To study the relationship of abortion and the expression of indoleamine 2, 3- dioxygenase （IDO） in villus and syncytiotrophoblast in vitro. Methods RT-PCR was applied to analyze the mRNA transcription of lDO in villus of normal pregnancy and inevitable abortion and JAR cells as well. Immunohistochemistry was applied to analyze the expression of IDO protein in villus. Western blot was applied to determinate the expression of IDO protein on cultured syncytiotrophoblast. Highperformance liquid chromatography was applied to determinate whether there was kynurenine in cell culture medium of syncytiotrophoblast. Results The expression of IDO mRNA and protein in villus of inevitable abortion was lower than that of normal pregnancy; IDO mRNA did not express in JAR cells. IDO protein expressed on cultured syncytiotrophoblast, and there was kynurenine in cell culture medium of syncytiotrophoblast. Conclusion Appropriate expression of IDO in villus is necessary.for maintenance of normal pregnancy and an active IDO protein expresses in syncytiotrophoblast.

Up-regulation of indoleamine 2,3-dioxygenase 1(IDO1)expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients

Background: Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan (Trp)catabolism have been demonstrated to play an important role in tumor immunosuppression. This study examined the expression and catalytic activity of IDO1 in penilesquamous cell carcinoma (PSCC) and explored their clinical significance.Methods: IDO1 expression level, serum concentrations of Trp and kynurenine (Kyn)were examined in 114 PSCC patients by immunohistonchemistry and solid-phaseextraction-liquid chromatography-tandem mass spectrometry. The survival was analyzed using Kaplan-Meier method and the log-rank test. Hazard ratio of death was analyzed via univariate and multivariate Cox regression. Immune cell types were definedby principal component analysis. The correlativity was assessed by Pearson’s correlation analysis.Results: The expression level of IDO1 in PSCC cells was positively correlatedwith serum Kyn concentration and Kyn/Trp radio (KTR;both P < 0.001) but negatively correlated with serum Trp concentration (P = 0.001). Additionally, IDO1 upregulation in cancer cells and the increase of serum KTR were significantly associated with advanced N stage (both P < 0.001) and high pathologic grade (P = 0.008and 0.032, respectively). High expression level of IDO1 in cancer cells and serumKTR were associated with short disease-specific survival (both P < 0.001). However, besides N stage (hazard radio [HR], 6.926;95% confidence interval [CI],2.458-19.068;P < 0.001) and pathologic grade (HR, 2.194;95% CI, 1.021-4.529;P = 0.038), only serum KTR (HR, 2.780;95% CI, 1.066-7.215;P = 0.036) was anindependent predictor for PSCC prognosis. IDO1 expression was positively correlated with the expression of interferon-𝛾 (IFN𝛾, P < 0.001) and immunosuppressivemarkers (programmed cell death protein 1, cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 and 2;all P < 0.05), and the infiltration ofimmune cells (including cytotoxic T lymphocytes, regulatory T lymphocytes, tumorassociated macrophages, and myeloid-derived suppressor cells;all P < 0.001) inPSCC tissues. Furthermore, the expression of IDO1 was induced by IFN𝛾 in a dosedependent manner in PSCC cells.Conclusions: IFN𝛾-induced IDO1 plays a crucial role in immunoediting andimmunosuppression in PSCC. Additionally, serum KTR, an indicator of IDO1catabolic activity, can be utilized as an independent prognostic factor for PSCC.

Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer

AIM To evaluate indoleamine-2,3-dioxygenase 1/cyclooxygenase 2(IDO1/COX2) expression as an independent prognostic biomarker for colorectal cancer(CRC) patients.METHODS We retrospectively studied the medical records of 95 patients who received surgical resection from August 2008 to January 2010. All patients were randomly assigned to adjuvant treatment with or without celecoxib groups after surgery. We performed standard immunohistochemistry to assess the expression levels of IDO1/COX2 and evaluated the correlation of IDO1/COX2 with clinicopathological factors and overall survival(OS) outcomes.RESULTS The expression of nuclear IDO1 was significantly correlated with body mass index(P < 0.001), and IDO1 expression displayed no association with sex, age, tumor differentiation, T stage, N stage, carcinoembryonic antigen, cancer antigen 19-9, CD3+ and CD8+ tumor infiltrating lymphocytes, and COX2. In univariate analysis, we found that nuclear IDO1(P = 0.039), nuclear/cytoplasmic IDO1 [hazard ratio(HR) = 2.044, 95% confidence interval(CI): 0.871-4.798, P = 0.039], nuclear IDO1/COX2(HR = 3.048, 95%CI: 0.868-10.7, P = 0.0049) and cytoplasmic IDO1/COX2(HR = 2.109, 95%CI: 0.976-4.558, P = 0.022) all yielded significantly poor OS outcomes. Nuclear IDO1(P = 0.041), nuclear/cytoplasmic IDO1(HR = 3.023, 95%CI: 0.585-15.61, P = 0.041) and cytoplasmic IDO1/COX2(HR = 2.740, 95%CI: 0.764-9.831, P = 0.038) have significantly poor OS outcomes for the CRC celecoxib subgroup. In our multivariate Cox model, high coexpression of cytoplasmic IDO1/COX2 was found to be an independent predictor of poor outcome in CRC(HR = 2.218, 95%CI: 1.011-4.48, P = 0.047) and celecoxib subgroup patients(HR = 3.210, 95%CI: 1.074-9.590, P = 0.037).CONCLUSION Our results showed that cytoplasmic IDO1/COX2 coexpression could be used as an independent poor predictor for OS in CRC.

Indoleamine 2,3-dioxygenase in tumor induced tolerance

Objective To review the recent studies about the role of indoleamine 2,3-dioxygenase （IDO） in tumor induced tolerance. Data sources Published articles （1978-2009） on IDO and tumor induced tolerance were selected from Medline. Study selection Articles selected were relevant to development of IDO in tumor induced tolerance. Of all originally identified articles, 50 specially addressed the stated purpose. Results Recent work has revealed IDO at high levels in tumors and in tumor-draining lymph nodes and a close relationship between IDO activity and the regulatory T cells. Conclusion Up-regulation of IDO is proven to be a mechanism of acquired tolerance in tumors, in which the closely coupled positive feedback system between IDO and reclulatorv T cells may be considered to play an important role.

Indoleamine 2,3-dioxygenase and regulatory dendritic cells contribute to the allograft protection induced by infusion of donor-specific splenic stromal cells

It has been reported that splenic stromal cells(SSCs)are capable of directly supporting the development of CD11c ^(lo)CD45RB^(+) IL-10-producing dendritic cells(DCs)from lineage-negative c-kit^(+) progenitor cells in the absence of exogenous cytokines.In vitro,DCs that differentiate on stromal cells suppress mixed leukocyte reaction responses and induce primary alloreactive CD4^(+) T cells to differentiate into IL-10-producing Tr1 cells.However,the precise mechanisms by which these SSCs exert their regulatory functions in vivo remain undefined.Furthermore,their possible contribution to the development of allograft transplantation tolerance has yet to be examined.Here,we have used both murine skin and cardiac allograft transplantation models to explore whether in vivo alloresponses can be regulated by infusion with donor-derived SSCs and to investigate the possible mechanisms by which SSCs exert regulatory effects to prevent allograft rejection.We show that intravenous SSC infusion prolonged murine skin allograft survival.The prolonged graft survival is associated with augmentation of the generation of regulatory DC subsets and CD4^(+) CD25^(+) Foxp3^(+) regulatory T cells(Tregs),as well as upregulation of the production of suppressive cytokines IL-10 and transforming growth factor(TGF)-b.Moreover,we found that indoleamine 2,3-dioxygenase and SSC-derived regulatory DCs contribute to allograft protection by infusion of donor-specific SSCs.Our data suggest that donor-derived SSCs could be used as a therapeutic target to promote transplantation tolerance.

Indoleamine 2,3-Dioxygenase in Endometriosis

Endometriosis(EMS)is a chronic inflammatory and estrogen-dependent gynecological disease characterized by the presence of endometrial tissue outside the uterine cavity.Although it is a benign disease,EMS is tumor-like in several aspects,which include unrestrained growth,decreased apoptosis,and aggressive invasion.EMS involves endocrine disorders and immunological factors.Indoleamine 2,3-dioxygenase(IDO)is an intracellular enzyme that catalyzes the initial and rate-limiting step of the metabolism of tryptophan.IDO is a potential candidate facilitating EMS development.Increased IDO expression in both eutopic and ectopic endometria of women with EMS is biologically important in aspects,which include regulation of endometrial stromal cell function and modulation of adjacent local immunocytes to generate a supportive microenvironment.In turn,the expression of IDO can be regulated by the complex endocrine-immune microenvironment networks in endometrial lesions.Here,we systematically review the roles of IDO in EMS to explore its pathological implications and treatment potential.

吲哚胺2,3-双加氧酶1在肝癌中的表达及其作用的初步研究

目的:探讨吲哚胺2,3–双加氧酶1(IDO1)在肝癌与癌旁组织中的表达情况及其作用。方法:应用公共数据库获取IDO1在泛癌和肝癌中的表达数据。应用免疫荧光染色法对82例肝癌和配对癌旁组织以及14例无配对的肝癌组织中IDO1的表达情况进行检测。皮下接种人源肝癌细胞SK–HEP1建立裸鼠皮下移植瘤模型,并予以IDO1抑制剂干预,通过苏木精–伊红(HE)病理染色和增殖细胞核抗原(PCNA)免疫组化染色评价IDO1抑制剂对肝癌细胞在体内生长速度的影响,免疫荧光染色检测瘤体组织中簇分化抗原(CD)4^(+)T细胞和CD8^(+)T细胞的浸润情况。结果:IDO1在多种癌组织中高表达。与癌旁组织相比,肝癌组织中IDO1的表达水平明显升高。病理染色结果示,抑制IDO1的表达可以明显降低肝癌移植瘤组织中PCNA的表达水平,增加CD4^(+)T细胞和CD8^(+)T细胞的浸润。结论:IDO1在肝癌组织中高表达,下调IDO1的表达可抑制肝癌细胞在体内增殖,延缓皮下瘤体的生长速率,增强免疫细胞对肿瘤细胞的应答。

吲哚胺2,3-双加氧酶1在子宫内膜异位症中的研究进展

子宫内膜异位症(EMT)是一种具有恶性肿瘤生物学特征的良性疾病,发病率高,治疗效果欠佳,极具侵袭性及复发性,对育龄女性的生育能力、心理健康及生活质量造成严重影响。目前,经血逆流、体腔上皮化生理论等多种学说仍无法完整解释其发病原因,越来越多的研究显示,免疫抑制在EMT发生和发展过程中具有重要作用。吲哚胺2,3-双加氧酶1(IDO1)是重要的免疫抑制分子,在免疫抑制及异常免疫激活发挥重要作用。IDO1的高表达可促进EMT的发生和发展,本文综述近年来IDO1与EMT相关性研究的进展,认为IDO1参与EMT的发展过程,影响EMT患者的分期,为疾病的临床诊断及治疗提供新方向。

丁酸钠通过下调细胞干扰素调节因子-1抑制鼻咽癌细胞CNE2吲哚胺-吡咯2,3-双加氧酶的表达

目的研究丁酸钠(NaB)抑制鼻咽癌细胞CNE2吲哚胺-吡咯2,3-双加氧酶(IDO)表达从而解除肿瘤免疫耐受的分子机制。方法体外培养人鼻咽癌上皮细胞CNE2,采用NaB和(或)IFN-γ处理CNE2细胞;免疫印迹检测CNE2细胞IDO的表达情况;RT-PCR检测JAK/STAT的细胞因子信号抑制因子1(SOCS1)和SOCS3的转录水平;Real time PCR检测CNE2细胞干扰素调节因子-1(IRF-1)的转录情况。结果在NaB作用下,CNE2细胞内IDO的表达减少,并且IFN-γ诱导的IDO表达也被显著抑制;SOCS1和SOCS3的转录水平未见改变;而IFN-γ诱导的IRF1转录受到NaB的显著抑制。结论 NaB抑制IFN-γ诱导的IDO表达,不是通过增加SOCS1和SOCS3的转录,而可能是通过下调IRF-1,抑制IFN-γ诱导的IDO表达。

吲哚胺2,3-双加氧酶1在胃癌中的研究进展

胃癌(Gastric Cancer,GC)是全球第五大最常见的恶性肿瘤,也是第四大癌症死亡相关原因。胃癌异质性明显,肿瘤微环境复杂,免疫检查点抑制剂虽然在晚期胃癌中展现出一定抗肿瘤疗效,但获益人群仍在少数。吲哚胺2,3-双加氧酶1(Indoleamine 2,3-Dioxygenase 1,IDO1)是色氨酸沿犬尿氨酸途径代谢中的关键酶,对肿瘤免疫逃逸起到了关键作用。目前已有多项研究表明IDO1在胃癌发生发展及幽门螺杆菌感染和EB病毒感染中发挥重要作用,所以靶向IDO1有望成为胃癌免疫治疗的新策略。本文就IDO1作用机制、IDO1在胃癌及相关疾病中的研究进展及IDO1抑制剂在胃癌中的应用前景进行综述。

吲哚胺2,3-双加氧酶1抑制剂的研究进展

吲哚胺2,3-双加氧酶1(indoleamine 2,3-dioxygenase 1,IDO1)是介导色氨酸沿犬尿氨酸途径分解代谢的限速酶。IDO1在肿瘤细胞和抗原呈递细胞(antigen presenting cells,APC)中存在过度表达现象,通过色氨酸的消耗及其代谢产物的聚积抑制局部免疫应答,使肿瘤细胞逃避免疫系统的监测,这与多数肿瘤治疗的不良预后有关。因此,IDO1是肿瘤免疫疗法的重要靶点。目前有多种骨架的IDO1抑制剂正在研究当中,其中3个已经进入了临床研究阶段。本文介绍了IDO1在肿瘤免疫耐受中的作用,并按结构分类,综述了IDO1抑制剂的研究进展。

瑞香素及噁唑类小分子抑制吲哚胺-2,3-双加氧酶1(IDO1)的研究

吲哚胺-2,3-双加氧酶1(indoleamine 2,3-dioxygenase 1,IDO1)在肿瘤免疫中发挥了重要作用,为了获得新型的IDO1小分子抑制剂,本研究利用He La细胞系建立了IDO1抑制剂筛选模型,筛选抑制IDO1活性的天然小分子化合物。将He La细胞接种于48孔板中,加入干扰素-γ(IFN-γ)诱导He La细胞中IDO1的表达,检测HeLa细胞分泌IDO1的酶代谢活性。对化合物库筛选后发现瑞香素(Daphnetin)和一个噁唑类小分子ZH-26能够抑制IDO1酶活性,采用Graph Pad Prism计算瑞香素和ZH-26的IC50值,结果显示瑞香素的IC50为16. 50±0. 33μM,ZH-26的IC50为4. 68±0. 21μM。进一步在HEK-293A细胞中过表达IDO1,不同浓度瑞香素和ZH-26处理细胞后也表现出对IDO1活性的抑制作用。采用Western blot方法发现瑞香素显著下调IFN-γ诱导的IDO1蛋白表达,而ZH-26则对IFN-γ诱导的IDO1的表达没有影响。综上,瑞香素和ZH-26在He La细胞内没有发现明显的细胞毒作用。本实验首次发现了瑞香素和ZH-26具有抑制IDO1的活性,不但为了解瑞香素这一天然来源临床药物的抗肿瘤机制提供新的视角,也为开发新的靶向IDO1的肿瘤免疫治疗候选药物奠定了基础。

吲哚胺-2,3双加氧酶和金属蛋白酶组织抑制剂-1在脓毒症患者中的表达及其与疾病的相关性分析

目的分析吲哚胺-2,3双加氧酶(IDO)和金属蛋白酶组织抑制剂-1(TIMP-1)在脓毒症患者中的表达及其与疾病的相关性。方法回顾性分析2016年1月—2019年8月收治的69例脓毒症患者的临床资料,根据患者病情严重程度分为脓毒症组35例和脓毒症休克组34例,另选取32例同时间段进行体检的健康者作为健康对照组。观察3组的IDO、TIMP-1水平以及急性生理与慢性健康状况评分系统Ⅱ(APACHEⅡ)评分情况,对比脓毒症患者的急诊脓毒症死亡风险(MEDS)和序贯器官衰竭评估(SOFA)评分。分析脓毒症患者的TIMP-1、IDO水平与MEDS、SOFA和APACHEⅡ评分的相关性。结果健康对照组IDO、TIMP-1水平以及APACHEⅡ评分均低于脓毒症组和脓毒症休克组,脓毒症组低于脓毒症休克组(P<0.05);脓毒症组的MEDS、SOFA评分均低于脓毒症休克组(P<0.01);脓毒症患者的IDO、TIMP-1水平与MEDS、SOFA、APACHEⅡ评分呈显著正相关(P<0.05,P<0.01)。结论脓毒症患者的TIMP-1和IDO水平与其病情严重程度及死亡风险具有相关性,IDO和TIMP-1水平越高,患者病情越严重,死亡风险越高。